哪里想瘦打哪里！FDA批准Kythera注射药物该公司在即

你才双下巴，你妻女都双下巴！所谓可人自是人皆有之。如果说赘肉是每一个希望仅有完美身型的“妹纸”或“汉纸”的背叛，那么一个喜感十足的双下巴算是是这些人的生死作对了。每一分钟，世界性都有人为自己的一张大饼脸而感到世间，虽然仅有一个肉感十足的双下巴捏上去是不下有肉感的，但是还是有很多人的体格使其无法经受一个双下巴之重。您可千万别疯，这甚至仍然催生出一个庞大的美国市场。根据美国皮肤上切除创会的报告研究显示，68%的美国人对自己的双下巴表示了“厌倦”之情。而亦然，最近Kythera母公司向FDA递交了其专门从事剿灭双下巴的美容施用式药品ATX-101。这种药品完成了许多“胖纸”梦寐以求的动态，哪里想瘦打哪里，算是是定点减肥。不要以为这种近乎温柔的药品只是一个疯话，在FDA下属的皮肤上和眼科药品专员会的无记名选举中会，研究员可是以17：0的超高得票一致赞同其母公司。或许是因为这些研究员中会也有很多饱受双下巴之苦吧。FDA也将著手于本年的5翌年13日之后对其采取之后决定。如果一切顺利的话，Kythera母公司著手于本年月份将该产品母公司，比对人士预计这一药品的年销售额将超过3亿美元之多。随着美容药品美国市场的日益变小，Kythera母公司算是是下了一步好棋。母公司于去年以8400万美元的价格从其前协力伙伴莱曼手里会归还了这种药品的全部权利。而Kythera母公司也希望借此为契机在美容药品美国市场中会入城拔寨。就在上个翌年，Kythera母公司和Actelion母公司定下意义2700万美元的协力协议，共同整合一种受挫过的炎炎症药品，而这种药品被认为或许整合出一种治疗外阴的药品。详细英文媒体报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.